Get started
Author

Nikulaa Parachuri

Brolucizumab—early real-world experience: BREW study
2020 · Ashish Sharma, Nilesh Kumar, et al. · Eye · 73
PDF
Biosimilars for Retinal Diseases: An Update
2020 · Ashish Sharma, Nilesh Kumar, et al. · American Journal of Ophthalmology · 53
Brolucizumab and immunogenicity
2020 · Ashish Sharma, Nilesh Kumar, et al. · Eye · 50
PDF
Approved biosimilar ranibizumab—a global update
2022 · Ashish Sharma, Mineo Kondo, et al. · Eye · 45
Semaglutide and the risk of diabetic retinopathy—current perspective
2021 · Ashish Sharma, Nikulaa Parachuri, et al. · Eye · 43
PDF
Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialists
2023 · Ashish Sharma, Arshad M. Khanani, et al. · International Journal of Retina and Vitreous · 41
PDF
Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occam’s Razor?
2021 · Ashish Sharma, Nilesh Kumar, et al. · Ocular Immunology and Inflammation · 35
PDF
Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world
2020 · Ashish Sharma, Nilesh Kumar, et al. · Eye · 34
PDF
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)
2023 · Ashish Sharma, Frank G Holz, et al. · Expert Opinion on Biological Therapy · 28
PDF
Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data
2019 · Ashish Sharma, M. Hafeez Faridi, et al. · Eye · 25
PDF
Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study)
2021 · Ashish Sharma, Nilesh Kumar, et al. · Eye · 20
PDF
Brolucizumab—foreseeable workflow in the current scenario
2021 · Ashish Sharma, Nilesh Kumar, et al. · Eye · 20
PDF
Pachydrusen: the epidemiology of pachydrusen and its relevance to progression of pachychoroid disease spectrum
2020 · Jay Sheth, Giridhar Anantharaman, et al. · Eye · 18
PDF
Understanding the Mechanisms of Fluid Development in Age-Related Macular Degeneration
2021 · Ashish Sharma, Nilesh Kumar, et al. · Ophthalmology Retina · 16
MII RetCam assisted smartphone-based fundus imaging (MSFI)—A boon for paediatric retinal imaging
2020 · Rajwinder Kaur, Harijot Singh, et al. · Eye · 16
PDF
Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI)
2024 · Ashish Sharma, Peter K. Kaiser, et al. · Eye · 15
PDF
Faricimab: Two in the Bush Is Proving Better than One in the Hand?
2021 · Ashish Sharma, Nilesh Kumar, et al. · Ocular Immunology and Inflammation · 15
PDF
Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians?
2022 · Ashish Sharma, Nilesh Kumar, et al. · Eye · 14
PDF
Ranizurel safety evaluation in real-world -(RaSER) study
2022 · Ashish Sharma, Jayshree Arunaprakash, et al. · American Journal of Ophthalmology Case Reports · 14
PDF
The Port Delivery System with ranibizumab—journey of mitigating vitreous hemorrhage
2021 · Ashish Sharma, Nikulaa Parachuri, et al. · Eye · 14
PDF
Brolucizumab—early experience with early extended interval regime in chronic centre involved diabetic macular oedema
2021 · Debdulal Chakraborty, Soumen Mondal, et al. · Eye · 14
PDF
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study
2025 · Ashish Sharma, Frank G. Holz, et al. · Journal of VitreoRetinal Diseases · 13
Brolucizumab—another anti-VEGF or beyond
2020 · Ashish Sharma, Nikulaa Parachuri, et al. · Eye · 13
PDF
Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression
2019 · Ashish Sharma, Nilesh Kumar, et al. · Eye · 13
PDF
Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity risk
2022 · Ashish Sharma, Nilesh Kumar, et al. · Expert Opinion on Biological Therapy · 12
Works count: 75
Citation count: 840
H-index: 15
I10-index: 29
Year
Topic
Type